Drugs / MT-251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07423299 | Jan 2026 → Mar 2027 expected | — | Mirador Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07423299 ↗ |
| Route | Intravenous | “single intravenous/subcutaneous dose of MT-251” NCT07423299 ↗ |
| Route | Subcutaneous | “single intravenous/subcutaneous dose of MT-251” NCT07423299 ↗ |